Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...

As we age, our bodies change, and our eyes are no exception. The good news is that with regular checks and a healthy lifestyle, most people can maintain ...

At this age, the headline premium is rarely the real story. Sub-limits, waiting periods and co-pay clauses quietly shape what you will actually get reimbursed.

Thank you, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals, Inc.'s Fourth Quarter and Full Year 2025 financial results and recent corporate developments ...

Duker indicated that EyePoint expects to report top line data for the Phase III LUGANO trial in mid-2026 with LUCIA data to follow closely, complete enrollment in the pivotal Phase III DME program in ...